+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Hemophilia A and B - Global Drug Forecast and Market Analysis to 2028

  • ID: 4850686
  • Report
  • August 2019
  • Region: Global
  • 228 pages
  • GlobalData
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • Alnylam Pharmaceuticals
  • Biogen
  • Chugai Pharmaceutical
  • Genetics Institute
  • Novo Nordisk
  • Sanofi
  • MORE
Hemophilia A and B - Global Drug Forecast and Market Analysis to 2028

Summary

Hemophilia A and B are rare, genetic, X-linked deficiencies in the blood clotting factors VIII (FVIII) and IX (FIX), respectively. Patients can be categorized as mild, moderate or severe depending on the percentage of circulating FVIII or FIX in their blood. Patients can be treated either on-demand or prophylactically using plasma-derived or recombinant replacement factors, the current standard of care.

Although these therapies are effective, they are associated with a great treatment burden. There is a significant unmet need for new therapies that can reduce the great treatment burden associated with intravenous administration, the frequency of prophylactic infusions, and the risk of developing neutralizing antibodies, or inhibitors, against replacement factors. Overall, the late-stage pipeline indicates an increase in the development of alternative coagulation promoters (ACPs) and gene therapies to further target these areas of significant unmet need. During the forecast window, Roche entered the market with the first monoclonal antibody targeting hemophilia A patients both with and without inhibitors, which addresses the unmet needs of frequency and route of administration. Sanofi are also to exploring a non-replacement approach and will enter the market with the ribonucleic acid (RNA) therapeutic, Fitusiran (previously Alnylam's), further ensuring cross-segment efficacy in patients both with and without inhibitors. The approval of these new products has begun to have a drastic effect on the hemophilia A and B treatment landscapes which is expected to continue through the forecast window. During this forecast window, several pharmaceutical companies, including BioMarin, uniQure and Pfizer/Roche (Spark Therapeutics), will also be launching new gene therapies that aim to cure, or at least reduce the severity of, hemophilia A and B and diminish inhibitors. If approved, gene therapies will pose a threat to existing hemophilia therapies.

The author projects the global hemophilia A and B marketplace to experience a significant growth during the forecast period. The author valued the hemophilia A and B market at $6.9B in 2018 in the 8MM and expects the market to increase to $9.3B in 2028 at a Compound Annual Growth Rate (CAGR) of 2.9%. This growth will be driven primarily by the increasing prophylactic treatment rates among patients, the continued use of recombinant products and the uptake of non-replacement therapies in the 8MM. However, cost constraints in the 8MM are expected to limit the premium pricing opportunities for new products such as late-to-market long-acting factor concentrates and new alternative coagulation promoters, thereby limiting the size of the hemophilia market.

This model covers the market forecast for marketed and late-stage pipeline hemophilia A and B therapeutics. The base year of this model is 2018, and the forecast period is 2018-2028.

Key Questions Answered
  • Which pipeline agents - replacement factors, alternative coagulation promoters and gene therapies - are the most promising and expected to launch in the 8MM?
  • What are the forecasted sales of these agents and what will be their impact in the hemophilia A and B market?
  • What are the main unmet needs in hemophilia A and B, and which pipeline drugs will fulfil these needs, and to what extent?
  • What are the current research and development (R&D) strategies being explored and how can developers incorporate these methods into their business strategy?
  • Key Opinions Leader (KOL) and payer insights across the 8MM, relating to the current treatment options and opinions on the late and early stage pipeline agents.
Key Highlights
  • The hemophilia A & B market is expected to grow at a CAGR of 2.9% until 2028, reaching a global value of $9.3B.
  • the author forecasts a marginal increase in prevalence rates across 8MM with AGR of 0.1% due to increased in prevalence rates across the US, Spain and UK.
  • Gene therapies will emerge as novel treatments for hemophilia A & B during the forecast period. Particularly, BioMarin’s first-to-market gene therapy, ValRox is likely to perform exceptionally well. Additionally, Roche’s Hemlibra is anticipated to achieve blockbuster status by the end of the forecast period.
  • Rising life expectancy for hemophilia patients leads to an increase in the size of the treated population.
  • Expected launches of expensive new drugs such as gene therapies, continued preference for prophylactic regimens, continued patient evolution from plasma-based to recombinant therapies are other significant drivers of market.
  • Limited scope for price premiums of late-to-market replacement products, high uptake of lower-priced drugs, rise in cost-consciousness and imposing market access barriers for the entry of expensive gene therapies are expected to affect market growth negatively.
  • Level of unmet needs in hemophilia patients is high but is expected to decrease due to advances in treatments and the introduction of novel therapies.
  • There are major market opportunities for the development of novel therapies, cheaper therapies for prophylaxis treatment, more effective treatments for hemophilia B patients with inhibitors and more therapies with convenient administration routes.
Scope

Overview of hemophilia A and B, including -
  • Disease overview - etiology, pathophysiology, symptoms, prognosis and quality of life
  • Epidemiology
  • Disease management - diagnosis and treatment
Patient segmentation -
  • Mild, Moderate, and Severe
  • Hemophilia A and B with and without inhibitors
  • Males and Females
  • All ages, Pediatrics and Adults
Annualized hemophilia A and B therapeutics market revenue and treatment usage patterns -
  • Patient shares and number of patients treated for marketed and pipeline products
  • Duration of and, daily and annual cost of therapies per patient
  • Product sales by usage and total sales of marketed and pipeline products
Key topics covered include -
  • Competitive assessment of marketed and pipeline products including SWOTs and, clinical and commercial positioning.
  • Unmet needs and opportunities including current and future level of attainment and gap analysis
  • Pipeline assessment - analysis of commercial and clinical attributes of promising drugs in clinical development and comprehensive analysis of promising approaches and emerging trends in early stage development
  • Analysis of the current and future players for the global hemophilia A and B market, including strength of marketed and pipeline products and trends in corporate strategy, profiles of leading companies in the hemophilia market.
  • Market outlook of the 8MM including forecast, key events and, market drivers and barriers.
Reasons to Buy

The report will enable you to -
  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the global hemophilia A and B market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global hemophilia market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Alnylam Pharmaceuticals
  • Biogen
  • Chugai Pharmaceutical
  • Genetics Institute
  • Novo Nordisk
  • Sanofi
  • MORE
1 Table of Contents
1.1 List of Tables
1.2 List of Figures

2 Executive Summary
2.1 Hemophilia A and B Market Expected to Grow to $9.3B by 2028
2.2 Inhibitor Segment Post-ACP Launch
2.3 ACPs and Gene Therapies to Radically Impact Hemophilia A and B Inhibitor and Non-Inhibitor Segments
2.4 Uncertainty in the Safety, Durability, and Availability of Gene Therapies Renders Curative Hemophilia Treatments a Continuing Unmet Need
2.5 Newcomers to Take Over Market Space from Established Companies
2.6 What Do Physicians Think?

3 Introduction
3.1 Catalyst
3.2 Related Reports
3.3 Upcoming Related Reports

4 Disease Overview
4.1 Etiology and Pathophysiology
4.1.1 Etiology
4.1.2 Pathophysiology
4.2 Classification
4.3 Symptoms
4.3.1 Hemophilia A and B
4.3.2 Inhibitors
4.4 Prognosis and Quality of Life

5 Epidemiology
5.1 Disease Background
5.2 Risk Factors and Comorbidities
5.3 Global and Historical Trends
5.4 Forecast Methodology
5.4.1 Sources
5.4.2 Forecast Assumptions and Methods
5.4.3 Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B
5.4.4 Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B by Severity
5.4.5 Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B by Inhibitor Status
5.4.6 Severity Among Inhibitors in Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B
5.4.7 Type of Treatment Among Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B
5.4.8 Diagnosed Prevalent Cases of Acquired Hemophilia
5.5 Epidemiological Forecast for Hemophilia A (2018-2028)
5.5.1 Diagnosed Prevalent Cases of Hemophilia A
5.5.2 Age-Specific Diagnosed Prevalent Cases of Hemophilia A
5.5.3 Sex-Specific Diagnosed Prevalent Cases of Hemophilia A
5.5.4 Diagnosed Prevalent Cases of Hemophilia A by Severity
5.5.5 Diagnosed Prevalent Cases of Hemophilia A with Inhibitors
5.6 Epidemiological Forecast for Hemophilia B (2018-2028)
5.6.1 Diagnosed Prevalent Cases of Hemophilia B
5.6.2 Age-Specific Diagnosed Prevalent Cases of Hemophilia B
5.6.3 Sex-Specific Diagnosed Prevalent Cases of Hemophilia B
5.6.4 Diagnosed Prevalent Cases of Hemophilia B by Severity
5.6.5 Diagnosed Prevalent Cases of Hemophilia B with Inhibitors
5.7 Epidemiological Forecast for Hemophilia A and Hemophilia B (2018-2028)
5.7.1 Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B
5.7.2 Age-Specific Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B
5.7.3 Sex-Specific Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B
5.7.4 Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B by Severity
5.7.5 Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B with Inhibitors
5.7.6 Severity Among Inhibitors in Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B
5.7.7 Type of Treatment Among the Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B
5.7.8 Diagnosed Prevalent Cases of Acquired Hemophilia
5.8 Discussion
5.8.1 Epidemiological Forecast Insight
5.8.2 Limitations of Analysis
5.8.3 Strengths of Analysis

6 Disease Management
6.1 Diagnosis and Treatment Overview
6.1.1 Treatment of Hemophilia A and B Without Inhibitors
6.1.2 Treatment of Hemophilia A and B Patients with Inhibitors
6.2 US
6.3 5EU
6.4 Japan
6.5 China

7 Competitive Assessment
7.1 Overview
7.2 Product Profiles - Hemophilia A
7.2.1 Short-Acting rFVIII
7.2.2 Long-Acting rFVIII
7.2.3 Alternative Coagulation Promoters
7.2.4 Plasma-Derived FVIII Concentrates
7.2.5 Desmopressin Acetate
7.3 Product Profiles - Hemophilia B
7.3.1 Short-Acting rFIX
7.3.2 Long-Acting rFIX
7.3.3 Plasma-Derived FIX Concentrates
7.4 Product Profiles - Hemophilia A and B with Inhibitors

8 Unmet Needs and Opportunities
8.1 Overview
8.2 Reduction in Risk of Inhibitor Development in Previously Untreated Patients
8.3 More Effective Treatments for Hemophilia B Patients with Inhibitors
8.4 More Therapies with Convenient Administration Routes
8.5 Treatments to Cure the Disease
8.6 Decreasing the Costs Associated with Prophylaxis and Promising Treatments
8.7 Individualized Prophylaxis

9 Pipeline Assessment
9.1 Overview
9.2 Promising Drugs in Clinical Development
9.3 Promising Approaches in Early-Stage Development
9.3.1 Alternative Coagulation Promoters - Tissue Factor Pathway Inhibitors
9.3.2 Gene Therapies
9.3.3 Replacement Strategies
9.3.4 Strategies to Prevent and Manage Inhibitors

10 Current and Future Players
10.1 Overview
10.2 Trends in Corporate Strategy
10.3 Company Profiles
10.3.1 Bayer
10.3.2 CSL Behring
10.3.3 Novo Nordisk
10.3.4 Pfizer
10.3.5 Roche
10.3.6 Sanofi
10.3.7 Takeda

11 Market Outlook
11.1 Global Markets
11.1.1 Forecast
11.1.2 Drivers and Barriers - Global Market
11.2 US
11.2.1 Forecast
11.2.2 Key Events
11.2.3 Drivers and Barriers
11.3 5EU
11.3.1 Forecast
11.3.2 Key Events
11.3.3 Drivers and Barriers - 5EU
11.4 Japan
11.4.1 Forecast
11.4.2 Key Events
11.4.3 Drivers and Barriers
11.5 China
11.5.1 Forecast
11.5.2 Key Events
11.5.3 Drivers and Barriers

12 Appendix

List of Tables
Table 1: Hemophilia A and B: Key Metrics in the Seven Major Markets, 2018-2028
Table 2: Relationship of Bleeding Severity with Clotting Factor Level.
Table 3: Comorbidities for Hemophilia
Table 4: 8MM Treatment Guidelines for Hemophilia
Table 5: The Most-Prescribed Hemophilia A and B Branded Drugs in the Global Markets, 2018
Table 6: Country Profile - US
Table 7: Country Profile - 5EU
Table 8: Country Profile - Japan
Table 9: Country Profile - China
Table 10: Leading Replacement Therapies for Hemophilia A and B and Patients with Inhibitors, 2019
Table 11: Marketed Plasma-Derived Replacement Therapies for Hemophilia A Patients, 2019
Table 12: Marketed Plasma-Derived Replacement Therapies for Hemophilia B Patients, 2019
Table 13: TFPI inhibitors - Early-Stage Pipeline, 2019
Table 14: Hemophilia A and B Gene Therapies - Early-Stage Pipeline, 2019
Table 15: Hemophilia A and B Recombinant Replacement Therapies - Early-Stage Pipeline, 2019
Table 16: Bayer’s Hemophilia Portfolio Assessment, 2019
Table 17: CSL Behring’s Hemophilia Recombinant Portfolio Assessment, 2019
Table 18: Novo Nordisk’s Hemophilia Recombinant Portfolio Assessment, 2019
Table 19: Pfizer’s Hemophilia Recombinant Portfolio Assessment, 2019
Table 20: Roche’s Hemophilia Recombinant Portfolio Assessment, 2019
Table 21: Bioverativ/Sobi’s Hemophilia Portfolio Assessment, 2019
Table 22: Takeda’s Hemophilia Recombinant Portfolio Assessment, 2019
Table 23: Hemophilia A and B Market - Global Drivers and Barriers, 2018-2028
Table 24: Key Events Impacting Sales for Hemophilia A and B in the US, 2018-2028
Table 25: Hemophilia A and B Market - US Drivers and Barriers, 2018-2028
Table 26: Key Events Impacting Sales for Hemophilia A and B Therapeutics in the 5EU, 2018-2028
Table 27: Hemophilia A and B Market - 5EU Drivers and Barriers, 2018-2028
Table 28: Key Events Impacting Sales for Hemophilia A and B in Japan, 2018-2028
Table 29: Hemophilia A and B Market - Japan Drivers and Barriers, 2018-2028
Table 30: Key Events Impacting Sales for Hemophilia A and B in China, 2018-2028
Table 31: Hemophilia A and B Market - China Drivers and Barriers, 2018-2028
Table 32: Key Historical and Projected Launch Dates for Hemophilia A and B
Table 33: Key Historical and Projected Patent Expiry Dates for Hemophilia A and B
Table 34: Average Body Weight Across the 8MM
Table 35: Physicians Surveyed

List of Figures
Figure 1: Global Sales Forecast by Country for Hemophilia A and B, 2018-2028
Figure 2: Competitive Assessment of Late-Stage Pipeline Agents for Hemophilia A and B, 2018-2028
Figure 3: Key Company Portfolio Positioning in Hemophilia A and B, 2018-2028
Figure 4: 8MM, Diagnosed Prevalence of Hemophilia A (%), All Ages, 2018
Figure 5: 8MM, Diagnosed Prevalence of Hemophilia B (%), All Ages, 2018
Figure 6: 8MM, Sources Used, Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B
Figure 7: 8MM, Sources Used, Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B, by Severity
Figure 8: 8MM, Sources Used, Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B with Inhibitors
Figure 9: 8MM, Sources Used, Severity Among Inhibitors in Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B
Figure 10: 8MM, Sources Used, Type of Treatment Among Hemophilia A and Hemophilia B Patients
Figure 11: 8MM, Sources Used, Diagnosed Prevalent Cases of Acquired Hemophilia
Figure 12: 8MM, Diagnosed Prevalent Cases of Hemophilia A, All Ages, Both Sexes, N, 2018
Figure 13: 8MM, Age-Specific Diagnosed Prevalent Cases of Hemophilia A, Both Sexes, N, 2018
Figure 14: 8MM, Sex-Specific Diagnosed Prevalent Cases of Hemophilia A, All Ages, N, 2018
Figure 15: 8MM, Diagnosed Prevalent Cases of Hemophilia A by Severity, Both Sexes, All Ages, N, 2018
Figure 16: 8MM, Diagnosed Prevalent Cases of Hemophilia A with Inhibitors, Both Sexes, All Ages, N, 2018
Figure 17: 8MM, Diagnosed Prevalent Cases of Hemophilia B, All Ages, Both Sexes, 2018
Figure 18: 8MM, Age-Specific Diagnosed Prevalent Cases of Hemophilia B, Both Sexes, 2018
Figure 19: 8MM, Sex-Specific Diagnosed Prevalent Cases of Hemophilia B, All Ages, N, 2018
Figure 20: 8MM, Diagnosed Prevalent Cases of Hemophilia B by Severity, Both Sexes, All Ages, N, 2018
Figure 21: 8MM, Diagnosed Prevalent Cases of Hemophilia B with Inhibitors, Both Sexes, All Ages, N, 2018
Figure 22: 8MM, Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B, Both Sexes, N, 2018
Figure 23: 8MM, Age-Specific Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B, Both Sexes, N, 2018
Figure 24: 8MM, Sex-Specific Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B, All Ages, N, 2018
Figure 25: 8MM, Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B by Severity, Both Sexes, All Ages, N, 2018
Figure 26: 8MM, Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B with Inhibitors, Both Sexes, All Ages, N, 2018
Figure 27: 8MM, Severity Among Inhibitors in Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B, Both Sexes, All Ages, N, 2018
Figure 28: 8MM, Type of Treatment Among the Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B, Both Sexes, All Ages, N, 2018
Figure 29: 8MM, Diagnosed Prevalent Cases of Acquired Hemophilia, All Ages, Both Sexes, N, 2018
Figure 30: Flowchart of the Diagnosis and Management of Hemophilia Patients, With and Without Inhibitors
Figure 31: Unmet Needs and Opportunities in Hemophilia A and B
Figure 32: Competitive Assessment of Late-Stage Pipeline Agents, 2018-2028
Figure 33: Overview of the Development Pipeline in Hemophilia, 2018-2028
Figure 34: Hemophilia A and B - Phase III Pipeline, 2019
Figure 35: Company Portfolio Analysis in Hemophilia A and B, 2018-2028
Figure 36: Global Sales for Hemophilia A and B by Drug Class, 2018-2028
Figure 37: Global Sales Forecast by Country for Hemophilia A and B, 2018-2028
Figure 38: Global Sales Forecast by Patient Segment, 2018-2028
Figure 39: Sales for Hemophilia A and B Therapeutics in the US by Drug Class, 2018-2028
Figure 40: Sales for Hemophilia A and B Therapeutics in the 5EU by Drug Class, 2018-2028
Figure 41: Sales for Hemophilia A and B Therapeutics in Japan by Drug Class, 2018-2028
Figure 42: Sales for Hemophilia A and B Therapeutics in China by Drug Class, 2018-2028
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Alnylam Pharmaceuticals
  • Alveron Pharma
  • Aprilbio
  • Aptevo Therapeutics
  • Bakusuaruta
  • Baxalta
  • Baxter
  • Bayer
  • Beijing Tiantan Biological Products
  • Biogen
  • BioMarin
  • BioReliance
  • Biotest
  • Bioverativ
  • Cangene Corporation
  • Catalyst Biosciences
  • The Chemo-Sero-Therapeutic Research Institute
  • China Biologic Products
  • Chengdu Rongsheng Pharmaceutical
  • Chugai Pharmaceutical
  • CSL Behring
  • Emergent BioSolutions
  • EpiVax
  • F. Hoffmann-La Roche
  • Freeline Therapeutics
  • GC Pharma
  • Genentech
  • Genetics Institute
  • Grifols
  • Hualan Biological Engineering
  • Idogen
  • Immuno
  • Ioproducts Laboratory
  • Japan Blood Products Organization
  • Kaifeng Pharmaceutical
  • Kedrion
  • Kymab
  • Laboratoire Français de Fractionnement et de Biotechnologies (LFB)
  • Novo Nordisk
  • Octapharma
  • Okklo Life Sciences
  • OPKO Biologics
  • Pfizer
  • Pharming Group
  • RegenxBio
  • Sanofi
  • Sangamo Therapeutics
  • Sanquin Pharmaceutical Services
  • Selecta Biosciences
  • Shanghai Baxter Healthcare
  • Shenzhen Geno-Immune Medical Institute
  • Shenzhen Weiwu Guangming Biological Preparations
  • Shire
  • SK Chemicals
  • Spark Therapeutics
  • St. Jude Children's Research Hospital
  • Swedish Orphan Biovitrum (SOBI)
  • Takeda Pharmaceutical
  • Ultragenyx Pharmaceutical
  • UniQure
  • Wyeth
Note: Product cover images may vary from those shown
Adroll
adroll